Workflow
Abacus Global Management Sues Coventry and its Chairman Alan Buerger for Defamation and Anticompetitive Conduct
Abacus LifeAbacus Life(US:ABL) Globenewswireยท2025-07-01 20:10

Core Viewpoint - Abacus Global Management, Inc. has filed a lawsuit against Coventry First LLC and its Chairman Alan Buerger, alleging a systematic campaign to disseminate false and misleading information aimed at damaging Abacus's reputation and market position [1][2][3]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Coventry and Buerger engaged in a multi-year effort to undermine Abacus's valuation practices, attempting to convince the market that Abacus overpays policyholders, leading to an overvaluation of its assets [3][4]. - Abacus asserts that Coventry's actions constitute tortious interference and defamation, as they have resorted to damaging Abacus's reputation instead of competing fairly [4]. - The lawsuit highlights that Abacus's financial practices are transparent and compliant with GAAP, contradicting Coventry's claims about Abacus's valuation methods [8][9]. Group 2: Impact of False Claims - Following a June 4, 2025 interview with Buerger, Abacus's stock dropped over 21%, resulting in a loss of more than $200 million in market capitalization due to the dissemination of false information [9][10]. - Abacus alleges that Coventry's campaign has caused substantial harm to its reputation, customer base, and investor relationships, with the company seeking hundreds of millions in damages [11][12]. - The lawsuit also points out that Coventry has a history of unsavory practices, including bid-rigging and involvement in illegal life insurance practices, which further undermines its credibility [11][12]. Group 3: Role of Short Seller - Morpheus Research is identified as a partner in disseminating Coventry's defamatory statements, with the short report released shortly after Buerger's interview, amplifying the false claims about Abacus [10][11]. - The lawsuit alleges that Morpheus's report echoed Coventry's misleading statements, contributing to the confusion among investors and market analysts [10][11].